The DEA plans to significantly increase the production quotas of psychedelic substances such as psilocybin, ibogaine, and cannabis-related compounds like THC for 2023 to meet growing research demands and support clinical trials. The proposed adjustments align with a broader recognition of the medical significance of psychoactive substances, marking a new era in scientific research.
In the world of science, there are areas that have been marginalized for years by the DEA and other agencies, and their potential often underrated. Psilocybin and other psychoactive substances are one of these topics currently experiencing a renaissance in scientific research.
For more news like this, download our free cannabis news app.
DEA Support for Scientific Research
The Drug Enforcement Administration (DEA), an American anti-drug agency, has taken steps toward significantly increasing its production quotas for 2023 for cannabis and psychedelic substances such as psilocybin and ibogaine.
The goal of these actions is to support research and clinical trials on these substances. According to information, the DEA plans to nearly double the amount of psilocybin, psilocin, and delta-9 THC produced compared to the initial levels set for this year. The DEA wants to increase ibogaine production fivefold and increase the production quota of “other cannabinoids” from 15,000 grams to 350,000 grams in 2023.
Increased Production in Response to Growing Interest
The increase in production is a response to growing interest in research on these substances. Production amounts of psilocybin, one of the main components of “magic mushrooms,” increased from 8,000 grams to a proposed 15,000 grams, reflecting the continuous increase in interest in studying psychoactive substances.
Moreover, the DEA proposes the production of 150 grams of ibogaine, which is five times the amount initially planned in December 2022. Although no changes have been made to the scope of 6.7 million grams of cannabis for the year, the DEA proposes the production of 628,460 grams of delta-9 THC, a 63% increase.
Doubling Production – A New Era of Research
One cannot ignore the decisions of the Drug Enforcement Administration (DEA) regarding the significant increase in the production of substances such as psilocybin, ibogaine, and THC. The planned production quantities for 2023 are evidence of a growing understanding of research needs in this field.
Understanding the Increase
Why do we observe such changes in production quotas? The answer lies in the growing interest in research on psychoactive substances. Advanced technologies and research methods allow for a more accurate analysis of the actions of these substances, translating into their potential application in treating various ailments.
Medical and Therapeutic Applications
Psychoactive substances are increasingly seen as a potential tool in treating ailments such as depression, PTSD, and anxiety disorders.
- MDMA: Studies on the use of MDMA in PTSD therapy show promising results. In 2023, Australia legalized the use of MDMA and psilocybin mushrooms in the treatment of post-traumatic stress disorder.
- Psilocybin: Research on “magic mushrooms” suggests their effectiveness in treating depression and many other mental illnesses. Psilocybin in tablets is often used by individuals practicing microdosing of psilocybin mushrooms.
- Ibogaine: It is indicated for its potential in treating opioid addiction.
In addition to the medical aspect, psychoactive substances also have significant cultural importance. In many cultures, they have been used for centuries for ritual or spiritual purposes. Modern society increasingly appreciates the value of these substances, not only as medicinal agents but also as tools for personal and spiritual development.
Future of Research on Psychoactive Substances
Considering the dynamic development in the field of research on psychoactive substances, it can be assumed that in the coming years, we will witness many breakthroughs. It is important to strive for a full understanding of the potential of these substances while taking care of patient safety and ethical aspects of research.
Research on psychoactive substances is a fascinating area that combines medicine, psychology, culture, and ethics. The modern world of science realizes the tremendous potential of these substances, which translates into intensified research and exploration of new applications in medicine and therapy.
Source: Federal Register
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Fakty Konopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.